Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia

Laryngoscope

Volumn 123, Issue 5, 2013, Pages 1092-1099

  Silva, B Maneesha ^a,b,c   Hosman, Anna E ^a,b,e   Devlin, Hannah L ^a,b,c,d   Shovlin, Claire L ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cautery; dietary salicylates; epistaxis; estrogens; laser; lifestyle; tamoxifen

Indexed keywords

ALCOHOL; AMINOCAPROIC ACID; ANTIESTROGEN; BEVACIZUMAB; HORMONE; OMEGA 3 FATTY ACID; SALICYLIC ACID DERIVATIVE; TRANEXAMIC ACID; VITAMIN;

ARTICLE; CACAO; COFFEE; CONTROLLED STUDY; DIET; DISEASE EXACERBATION; DISEASE SEVERITY; EPISTAXIS; FEMALE; FOOD; FRUIT; GARLIC; GINGER; GINKGO BILOBA; GINSENG; HUMAN; HUMIDIFIER; LIFESTYLE; LUBRICATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RED WINE; RENDU OSLER WEBER DISEASE; RISK FACTOR; SPICE; ADULT; AGED; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DIET; EPISTAXIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879306887     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23893     Document Type: Article

References (62)

1. Shovlin CL,. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-219.
2. AAssar OS, Friedman CM, White RI Jr,. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991; 101: 977-980.
3. Kjeldsen AD, Vase P, Green A,. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999; 245: 31-39.
4. Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002; 19: 140-148.
5. Abdalla SA, Letarte M,. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110.
6. Park S, Wankhede M, Lee Y, et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 2009; 119: 3487-3496.
7. Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420-428.
8. McDonald J, Bayrak-Toydemir P, Pyeritz RE,. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med 2011; 13: 607-616.
9. Faughnan M, Palda V, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet 2011; 48: 73-87.
10. Ingrand I, Ingrand P, Gilbert-Dussardier B, et al. Altered quality of life in Rendu-Osler-Weber disease related to recurrent epistaxis. Rhinology 2011; 49: 155-162.
11. Loaec M, Moriniere S, Hitier M, Ferrant O, Plauchu H, Babin E,. Psychosocial quality of life in hereditary haemorrhagic telangiectasia patients. Rhinology 2011; 49: 164-167.
12. Mahoney EJ, Shapshay SM,. Nd-YAG laser photocoagulation for epistaxis associated with hereditary hemorrhagic telangiectasia. Laryngoscope 2005; 115: 373-375.
13. Harvey RJ, Kanagalingam J, Lund VJ,. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 2008; 22: 182-187.
14. Van Cutsem E, Rutgeerts P, Vantrappen G,. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990; 335: 953-955.
15. Yaniv E, Preis M, Hadar T, Shvero J, Haddad M,. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119: 284-288.
16. Karnezis TT, Davidson TM,. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121: 636-638.
17. Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM,. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 2012; 33: 349-351.
18. Sabba C, Gallitelli M, Palasciano G,. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 926.
19. Saba HI, Morelli GA, Logrono LA,. Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994; 330: 1789-1790.
20. Morales-Angulo C, Perez del Molino A, Zarrabeitia R, Fernandez A, Sanz-Rodriguez F, Botella LM,. Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid. Acta Otorrinolaringol Esp 2007; 58: 129-132.
21. de Gussem E, Snijder R, Disch F, Zanen P, Westermann C, Mager J,. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009; 47: 85-88.
22. Lund V, Howard D,. A treatment algorithm for the management of epistaxis in hereditary haemorrhagic telangiectasia. Am J Rhinol 1999; 13: 319-322.
23. Folz BJ, Tennie J, Lippert BM, Werner JA,. Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 2005; 43: 40-46.
24. Swain AR, Dutton SP, Truswell AS,. Salicylates in foods. Am Diet Assoc 1985; 85: 950-960.
25. Swain AR,. The role of natural salicylates in food intolerance. (PhD Thesis, University of Sydney). 1988. Available at: http://www.sswahs.nsw.gov.au/ rpa/allergy/research/students/1988/AnneSwainPhDThesis.pdf.
26. Paterson JR, Srivasatava R, Baxter GJ, Graham AB, Lawrence JR,. Salicylic acid content of spices and its implications. J Agric Food Chem 2006; 54: 2891-2896.
27. Stanger MJ, Thompson LA, Young AJ, Lieberman HR,. Anticoagulant activity of select dietary supplements. Nutr Rev 2012; 70: 107-117.
28. Pribitkin ED, Boger D,. Herbal therapy: What every facial plastic surgeon must know. Arch Facial Plastic Surg 2001; 3: 127-132.
29. Ciocon JO, Ciocon DG, Galindo DJ,. Dietary supplements in primary care: Botanicals can affect surgical outcomes and follow-up. Geriatrics 2004; 58: 20-24.
30. Spolarich AE, Andrews L,. An examination of the bleeding complications associated with herbal supplements, antiplatelet and anticoagulant medications. J Dent Hyg 2007; 81: 67.
31. Violi F, Pignatelli P, Basili S,. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation 2010; 121: 1033-1044.
32. Pope LER, Hobbs CGL,. Epistaxis: an update on current management. Postgrad Med J 2005; 81: 309-314.
33. Saban Y, Amodeo CA, Bouaziz D, Polselli R,. Nasal arterial vasculature: medical and surgical applications. Arch Facial Plast Surg 2012, doi: 10.1001/archfacial.2012.202. [Epub ahead of print].
34. Sautter NB, Smith TL,. Hereditary hemorrhagic telangiectasia-related epistaxis: innovations in understanding and management. Int Forum Allergy Rhinol 2012; 2: 422-431.
35. Pan SF, Sun Y, Li F, et al. Effects of Yunnan Baiyao on peri-operative bleeding of patients undergoing cervical open-door laminoplasty: a multi-center randomised double-blind placebo-control trial. Zhonghua Yi Xue Za Zhi 2006; 86: 1888-1890.
36. Li NC, Pan BN, Wang HJ, et al. The effect of Yunnan Baiyao on reduction of intra-operative bleeding of the patients undergoing transurethral resection of prostate. Zhonghua Yi Xue Za Zhi 2007; 87: 1017-1020.
37. Tang ZL, Wang X, Yi B, Li ZL, Liang C, Wang XX,. Prophylactic administration of Yunnan Baiyao capsule reduces intra-operative blood loss in orthognathic surgery. Zhonghua Kou Qiang Yi Xue Za Zhi 2008; 43: 542-545.
38. Tang ZL, Wang X, Yi B, Li ZL, Liang C, Wang XX,. Effects of the preoperative administration of Yunnan Baiyao capsules on intraoperative blood loss in bimaxillary orthognathic surgery: a prospective, randomised, double-blind, placebo-controlled study. Int J Oral Maxillofac Surg 2009; 38: 261-266.
39. Djerassi I, Farber S, Roy AR, Yoshimura H,. Effects of soybean phosphatides on the hemorrhagic tendency due to thrombocytopenia. J Clin Invest 1962; 41: 770-778.
40. Okamoto K, Horisawa R,. Soy products and risk of an aneurysmal rupture subarachnoid hemorrhage in Japan. Eur J Cardiovasc Prev Rehabil 2006; 13: 284-287.
41. Livesey JA, Manning R, Meek JH, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax 2012; 67: 328-333.
42. Tay HL, Evans JM, McMahon AD, MacDonald TM,. Aspirin, nonsteroidal anti-inflammatory drugs, and epistaxis. A regional record linkage case control study. Ann Otol Rhinol Laryngol 1998; 107: 671-674.
43. Srivastava KC, Bordia A, Verma SK,. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids 1995; 52: 223-227.
44. Shah BH, Nawaz Z, Pertani SA, et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol 1999; 58: 1167-1172.
45. Mayanglambam A, Dangelmaier CA, Thomas D, Damodar Reddy C, Daniel JL, Kunapuli SP,. Curcumin inhibits GPVI-mediated platelet activation by interfering with the kinase activity of Syk and the subsequent activation of PLCgamma2. Platelets 2010; 21: 211-220.
46. Yang X, Thomas DP, Zhang X, et al. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 2006; 26: 85-90.
47. Li H, Forstermann U,. Red wine and cardiovascular health. Circ Res 2012; 111: 959-961.
48. Mukamal KJ, Massaro JM, Ault KA, et al. Alcohol consumption and platelet activation and aggregation among women and men: the Framingham Offspring Study. Alcohol Clin Exp Res 2005; 29: 1906-1912.
49. Rein D, Paglieroni TG, Wun T, et al. Cocoa inhibits platelet activation and function. Am J Clin Nutr 2000; 72: 30-35.
50. Pearson DA, Paglieroni TG, Rein D, et al. The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Thromb Res 2002; 106: 191-197.
51. Murphy KJ, Chronopoulos AK, Singh I, et al. Dietary flavanols and procyanidin oligomers from cocoa (Theobroma cacao) inhibit platelet function. Am J Clin Nutr 2003; 77: 1466-1473.
52. Heptinstall S, May J, Fox S, Kwik-Uribe C, Zhao L,. Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J Cardiovasc Pharmacol 2006; 47: S197-S205.
53. Innes AJ, Kennedy G, McLaren M, Bancroft AJ, Belch JJ,. Dark chocolate inhibits platelet aggregation in healthy volunteers. Platelets 2003; 14: 325-327.
54. Hermann F, Spieker LE, Ruschitzka F, et al. Dark chocolate improves endothelial and platelet function. Heart 2006; 92: 119-120.
55. Flammer AJ, Hermann F, Sudano I, et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007; 116: 2376-2382.
56. Hamed MS, Gambert S, Bliden KP, et al. Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. South Med J 2008; 101: 1203-1208.
57. Dyerberg J, Bang HO,. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979; 2: 433-435.
58. Moertl D, Berger R, Hammer A, et al. Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost 2011; 106: 457-465.
59. Cohen MG, Rossi JS, Garbarino J, et al. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel. Thromb Res 2011; 128: 335-340.
60. Thorwest M, Balling E, Kristensen SD, et al. Dietary fish oil reduces microvascular thrombosis in a porcine experimental model. Thromb Res 2000; 99: 203-208.
61. Harris WS,. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol 2007; 99: 44C-46C.
62. Phang M, Lazarus S, Wood LG, Garg M,. Diet and thrombosis risk: nutrients for prevention of thrombotic disease. Semin Thromb Hemost 2011; 37: 199-208.